Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Experts report new guidelines for clinical trial design in patients with brain metastases

Clinical trials of new anti-cancer therapies have often excluded patients whose disease has spread to the brain or central nervous system (CNS) or, if such patients were allowed on trial, trials have often failed to clearly capture information on the drug's effect in the brain.

30 Dec 2017

Nanobiotix receives FDA approval for first immuno-oncology trial

NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the U.S. Food and Drug Administration has approved its Investigational New Drug Application for NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors, activated by stereotactic ablative radiotherapy (SABR) and administered in combination with an anti-PD1 antibody (nivolumab or pembrolizumab).

26 Dec 2017

New first line combination therapy shows promising results in patients with advanced NSCLC

A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.

7 Dec 2017

'Aggressive' surgery for early stage lung cancer provides better outcomes

Patients with early stage lung cancer live longer when they receive a lobectomy- the most common type of operation for the disease- rather than a less extensive operation or radiation treatment, according to a study published online today in The Annals of Thoracic Surgery.

30 Nov 2017

Study: Alectinib 600 mg more effective than standard therapy in Asian ALK positive NSCLC patients

A subanalysis of the phase III ALEX study has shown that alectinib 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC), researchers report at the ESMO Asia 2017 Congress.

20 Nov 2017

Osimertinib provides progression-free survival benefit to Asian patients with EGFR-mutated NSCLC

Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress, sumultaneously published in The New England Journal of Medicine.

20 Nov 2017

Elevated levels of chronic stress hormones may promote EGFR inhibitor resistance in NSCLC patients

Elevated levels of chronic stress hormones, such as those produced by psychological distress, may promote resistance to drugs commonly used to treat lung cancer patients with EGFR mutations, according to new research from The University of Texas MD Anderson Cancer Center.

9 Nov 2017

FDG PET/CT imaging shows correlation between amount of cfDNA and cancer aggressiveness

Italian researchers have demonstrated a better way of determining the aggressiveness of tumors in patients with advanced non-small cell lung cancer (NSCLC).

7 Nov 2017

Gut bacteria may influence the response to certain cancer therapies finds study

A latest study has found that patients with advanced melanoma or skin cancer who had a specific bacteria in their gut had a more favorable response to certain types of cancer treatment or immunotherapy. The study from the University of Texas was published in the latest issue of the journal Science.

3 Nov 2017

Cancer researchers make breakthrough in identifying genetic changes during immunotherapy

For some cancer patients, the road to remission and healing can have its share of speed bumps. That's particularly true of patients with non-small cell lung cancer (NSCLC) who develop a secondary, or acquired, resistance to immunotherapy, which initially was effective against their tumors.

28 Oct 2017

Dartmouth study uncovers three novel genetic biomarkers for lung cancer

Both environmental and genetic risk factors contribute to development of lung cancer. Tobacco smoking is the most well-known environmental risk factor associated with lung cancer. A Dartmouth research team led by Yafang Li, PhD, has conducted a study to display that gene-smoking interactions play important roles in the etiology of lung cancer.

26 Oct 2017

Survival of early stage lung cancer patients improves with advancement in surgery, radiation

With the advancement of surgical and radiation therapy strategies for stage 1 non-small-cell lung cancer (NSCLC), more patients are being treated, resulting in higher survival rates, according to a study published online today in The Annals of Thoracic Surgery.

26 Oct 2017

FDA approved drug found to have anti-cancer activity against previously unknown targets

Developing new drugs to treat cancer can be a painstaking process taking over a decade from start to Food and Drug Administration approval. Scientists are trying to develop innovative strategies to identify and test new drugs quicker and more efficiently.

10 Oct 2017

Blood test may predict treatment outcomes for patients with localized NSCLC

A new study demonstrates that a blood test to detect cancer may predict treatment outcomes for patients with localized non-small cell lung cancer (NSCLC) and afford physicians additional lead time to personalize treatment for recurrent disease.

28 Sep 2017

BWH researchers identify new rare genetic cause of peritoneal mesothelioma

Mesothelioma is a rare and aggressive tumor that, in many cases, results from exposure to asbestos. But over the last several decades, other causes of the disease have emerged, including treatment with high-intensity therapeutic radiation and, more recently, an inherited genetic mutation.

14 Sep 2017

FDA grants approval for new biosimilar to treat multiple types of cancer

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

14 Sep 2017

Scientists find new strategy for overcoming resistance to drugs in lung cancer patients

Research at the University of Southern Denmark has revealed that a new combination of clinically tested drugs inhibits the growth of tumors, thereby potentially improving patients' survival.

8 Sep 2017

Combination treatment provides positive results for people with advanced melanoma

In a two-year UCLA-led study, nearly two-thirds of people with advanced melanoma responded positively to a treatment that combines the immunotherapy drug pembrolizumab with a herpes virus called talimogene laherpareovec, or T-VEC.

8 Sep 2017

Blood tumor markers could be useful in monitoring therapeutic outcomes for lung cancer patients

For many years, oncologists have known that cancers can secrete complex molecules into the blood and that levels of these molecules can be easily measured. These so-called 'tumor markers' are traditionally associated with a single dominant cancer type, for example Prostate Specific Antigen (PSA) linked to prostate cancer, Carcinoembryonic antigen (CEA) to colorectal cancer, CA125 to ovarian cancer, CA19.9 to pancreatic cancer and CA27.29 to breast cancer.

6 Sep 2017

Tumor irradiation may prolong survival of NSCLC patients undergoing novel chemotherapy formulation

Patients with unresectable, or inoperable, lung cancer are often given a dismal prognosis, with low rates of survival beyond a few years.

26 Aug 2017